By Monica Li, Dezan Shira & Associates’ Beijing Office
On April 21, 2021, the Embassy of the People’s Republic of China in the United States of America published the Notice on the Testing Requirements for China-Bound Passengers Departing from Dallas after Inoculated with COVID-19 Vaccines (the Notice). According to the Notice, China will accept vaccination records in travel applications from people who have been inoculated in the US with COVID-19 vaccines made by US vaccine producers.
In this article, we try to provide clarity around how the Notice will impact China’s entry policy by China-bound passengers from the US.
China’s requirements on China-bound passengers’ nucleic acid and antibody blood test results have been adjusted several times as the epidemic prevention and control situation keeps developing in the US.
With the publishing of the said Notice, China-bound passengers can be divided into two groups: uninoculated passengers and inoculated passengers, who are subject to different testing requirements.
For uninoculated passengers, among other criteria, the testing requirements for entering China are as follows:
After obtaining the test results, non-Chinese passengers need to obtain a QR code with an “HDC” mark via the website: https://hrhk.cs.mfa.gov.cn/H5/. For Chinese passengers, they will need to obtain a green health code with the “HS” mark via the WeChat Health Code app.
According to the vaccine type, the inoculated passengers can be further divided into two sub-groups: passengers inoculated with inactivated vaccine and passengers inoculated with the non-inactivated vaccine.
For passengers inoculated with the inactivated vaccine (including China-made vaccines), the testing requirements are as follows:
Similarly, after obtaining the test results, non-Chinese passengers need to obtain a QR code with an “HDC” mark via the website: https://hrhk.cs.mfa.gov.cn/H5/. For Chinese passengers, they will need to obtain a green health code with the “HS” mark via the WeChat Health Code app. They will need to upload the Letter of Commitment on COVID-19 Vaccination and the vaccination certificate, together with the test reports
For passengers inoculated with the non-inactivated vaccine (mainly refer to Pfizer, Moderna, Johnson & Johnson produced vaccines), the testing requirements are:
After obtaining the test results, non-Chinese passengers need to obtain a QR code with an “HDC” mark via the website: https://hrhk.cs.mfa.gov.cn/H5/ and Chinese passengers need to obtain a green health code with the “HS” mark via the WeChat Health Code app.
They will need to submit the Letter of Commitment on COVID-19 Vaccination, the vaccination certificate (with all required doses administered), and the test reports (especially the IgM antibody test against N protein result).
Based on the above information, we answer some of the most frequently asked questions:
A1: No, it does not. The entry policy still requires passengers to follow the rules/procedures as summarized and posted by us here: How Can Foreigners Enter China Under the COVID-19 Travel Restrictions?, that is, only those who satisfy visa requirements can enter China.
One may think that the Notice tells how US-vaccinated passengers can be granted a visa and enter China. However, this is a misunderstanding. The Notice actually only clarifies the testing requirement of those inoculated with US vaccines. It doesn’t mean the visa facilitation will be applied to them.
A2: No, apply to those who have been inoculated with China-made vaccines only.
A3: Los Angeles, San Francisco, Seattle, New York, Detroit, and Dallas.
A4：Yes, getting inoculated with COVID-19 vaccines does not exempt the passenger from observing quarantine or any other epidemic prevention and control obligations of China.
Dezan Shira & Associates are devoted to providing China Briefing readers with the most updated and correct interpretation of the entry policies of China. If there is any confusion, please kindly turn to us for further discussion.
Note: This article only applies to China-bound passengers from the United States of America. Should readers from other countries/regions have interests to know more details about the policies applicable to their own countries/regions, kindly let us know separately email@example.com.
China Briefing is written and produced by Dezan Shira & Associates. The practice assists foreign investors into China and has done so since 1992 through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Dongguan, Zhongshan, Shenzhen, and Hong Kong. Please contact the firm for assistance in China at firstname.lastname@example.org.
Dezan Shira & Associates has offices in Vietnam, Indonesia, Singapore, United States, Germany, Italy, India, and Russia, in addition to our trade research facilities along the Belt & Road Initiative. We also have partner firms assisting foreign investors in The Philippines, Malaysia, Thailand, Bangladesh.
Previous Article « Optimizing Profit in a Dividend Repatriation by DTA: A Case Study
Next Article Investing in Inland China: Chongqing, Gateway to China’s West »
Doing Business in China 2021 is designed to introduce the fundamentals of investing in China. Compiled by the ...
Having suffered through the worst of the COVID-19 outbreak in the initial months of the year, China now offers...
Dezan Shira & Associates´ brochure offers a comprehensive overview of the services provided by the firm. With...
Dezan Shira & Associates helps
businesses establish, maintain,
and grow their operations.
Stay Ahead of the curve in Emerging Asia. Our subscription service offers regular regulatory updates,
including the most recent legal, tax and accounting changes that affect your business.